Table 4.
NOD2 and LCT mutation distribution in MAP infected and non-infected individuals among Crohn’s disease (CD), ulcerative colitis (UC) and in control (HC) cohorts [n(%)]
|
Number of mutations |
CD (n = 173) |
UC (n = 105) |
HC (n = 188) |
|||
|---|---|---|---|---|---|---|
| MAP + | MAP - | MAP + | MAP - | MAP + | MAP - | |
|
NOD2 | ||||||
|
0 |
29 (16.76) |
103 (59.54) |
19 (18.10) |
77 (40.96) |
77 (40.96) |
87 (46.28) |
|
1 |
7 (4.05) |
26 (15.03) |
1 (0.95) |
7 (6.67) |
8 (4.26) |
16 (8.51) |
|
2 |
1 (0.58) |
7 (4.05) |
0 (0.00) |
1 (0.95) |
0 (0.0) |
0 (0.00) |
|
LCT | ||||||
|
0 |
27 (15.61) |
109 (63.01) |
14 (13.33) |
64 (60.95) |
73 (38.83) |
80 (42.55) |
| 1 | 10 (5.78) | 27 (15.61) | 6 (5.71) | 21 (20.00) | 12 (6.38) | 23 (12.23) |
No significant differences were detected among groups except for CD versus HC NOD2 0 and CD versus HC LCT 0 (p < 0.0001).